Patients who were bridged/downstaged to orthotopic liver transplantation (OLT) by transarterial chemoembolization (TACE) or yttrium-90 (Y90) radioembolization had similar outcomes, even though Y90 patients waited longer for OLT. The researchers also observed a trend towards improved recurrence-free… Read More
In patients with hepatocellular carcinoma (HCC), a regimen of prophylactic dexamethasone prior to transcatheter arterial chemoembolization (TACE) is more effective at preventing fever, anorexia, and nausea/vomiting than a control regimen. “To our knowledge, this is the first well-designed… Read More
IL-6 cytokine
Cytokine values may help to identify patients who will benefit from yttrium-90 (Y-90) radioembolization of liver malignancies. Researchers reported their findings in Cardiovascular and Interventional Radiology. The observational study included data from 34 consecutive patients who were scheduled… Read More
tumor cells
Combined treatment with first-line chemotherapy and selective internal radiation therapy (SIRT) led to a better survival rate in patients whose liver metastases had originated from right-sided primary colorectal tumors, compared with patients who were treated with chemotherapy alone. The survival… Read More
Radioembolization with yttrium-90 (Y90) in patients who have previously undergone major hepatic resection seems to be safe and effective, researchers reported. The retrospective study evaluated data from 15 patients (10 male, 5 female) with primary or secondary hepatic malignancies who underwent… Read More
risk score
Maximum tumor size, intrahepatic tumor distribution, and the presence of portal vein tumor thrombosis (PVTT) are useful factors in predicting the likelihood of overall survival for patients with hepatocellular carcinoma (HCC) and extrahepatic spread (EHS). Researchers reported their findings in the… Read More
Patients with unresectable colorectal liver metastases survive longer if they are treated with a combination of systemic treatment and local treatment with radiofrequency ablation and with or without resection, according to the final results of the CLOCC study. The phase II, randomized trial… Read More
The modified RENAL (mRENAL) score can predict the likelihood of complications after percutaneous renal cryoablation, while tumor size can predict whether recurrence is likely. Researchers reported their findings in the June JVIR. The RENAL score includes Radius (tumor size as maximal diameter),… Read More
hepatocellular carcinoma
Drug-eluting embolic (DEE) transarterial chemoembolization agents are able to deliver doxorubicin to targeted tissues even 80 days after chemoembolization, according to a study published in the June JVIR. Hadrien D’inca, PhD, and colleagues, examined 4 patients with hepatocellular carcinoma who… Read More
Antibiotic prophylaxis does not appear to reduce the risk of infectious complications after embolotherapy in patients who have previously undergone biliary procedures, according to an abstract presented at the 2017 World Conference on Interventional Oncology in Boston, Massachusetts. In a… Read More